首页/数据集/AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination

AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination

ChEBI2025-12-15 更新2026-07-12 收录

多发性骨髓瘤药物筛选

癌症联合用药效应

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-15466 数据链接链接失效反馈

官方服务：

资源简介：

AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination

应用场景：

创建时间：

2025-12-15

多发性骨髓瘤药物筛选

高通量药物敏感性分析

Abstract Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numer

Zenodo2025-02-23 更新60

WNK463 effect on JJN3 cells. WNK463 effect on JJN3 cells

多发性骨髓瘤药物筛选

细胞功能组学分析

This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series

NIAID Data Ecosystem30

NCATS_MIPE_人骨髓瘤细胞系药物筛选数据集4_0版

多发性骨髓瘤药物筛选

肿瘤药理学

本数据集包含针对47种人骨髓瘤细胞系（HMCL）开展的大规模药物筛选结果，涵盖1912种小分子化合物在11个剂量下的测试数据。提供原始数据、处理后数据，以及药物和细胞系元数据、关键特征表征等支持信息，用于发现多发性骨髓瘤治疗药物及疗效相关生物标志物。 Zenodo平台（数据集）、GitHub仓库https://github.com/khughitt/hmcl-drug-screen-pipelin

海数据30

Small-molecule inhibitor JQ1 effect on multiple myeloma cell lines

多发性骨髓瘤药物筛选

抑制剂药效评估

Small-molecule inhibitor JQ1 effect on multiple myeloma cell lines

ChEBI2011-09-01 更新30

Human Myeloma Cell Line (HMCL) NCATS MIPE 4.0 Drug Screen Dataset

多发性骨髓瘤药物筛选

肿瘤细胞系药效评估

ABSTRACT: Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numer

Zenodo2025-02-23 更新30

AMO-1 cell line after 8h of Ceritinib, Carfilzomib treatment and their combination

资源简介：

相关数据集